| Size | Price | Stock | Qty |
|---|---|---|---|
| 5mg |
|
||
| 10mg |
|
||
| Other Sizes |
| ln Vitro |
RUNX1/ETO-IN-1 (compound M23) (96 h) inhibited cell viability in the AML cell line SKNO-1 carrying the t(8;21) translocation (leading to RUNX1/ETO expression) with an IC50 value of 62.14 µM [1]. RUNX1/ETO-IN-1 (20–200 µM) reduced the thermostability of NHR2 in a concentration-dependent manner (ΔTm = -1.6°C), which may be achieved by interfering with tetramer-dimer balance [1]. RUNX1/ETO-IN-1 (50–100 µM, 24 h) arrested the cell cycle of SKNO-1 cells and may induce apoptosis, but had no such effect in THP-1 cells [1]. RUNX1/ETO-IN-1 (50-100 µM, 24 hours) induced SKNO-1 cell apoptosis by increasing the activity of caspase-3 and -7, but had no effect on THP-1 cells and healthy NC-NC control cells [1]. RUNX1/ETO-IN-1 (25-50 µM, 3 days) promoted SKNO-1 cell differentiation by increasing CD11b expression, but had no effect on K562 cells and THP-1 cells [1].
|
|---|---|
| Cell Assay |
Cell viability assay [1]
Cell Types: RUNX1/ETO negative THP-1, K562, HL-60 cells, RUNX1/ETO dependent SKNO-1 cells, B lymphoblasts Tested Concentrations: 1-100 μM Incubation Duration: 72 h Experimental Results: The highest sensitivity was observed for SKNO-1 cells; the effect on RUNX1/ETO negative THP-1, K562, and HL-60 cells was relatively small; and there was no effect on B lymphoblasts. Cell cycle analysis [1] Cell Types: RUNX1/ETO negative THP-1 cells and RUNX1/ETO positive SKNO-1 cells Tested Concentrations: 50, 100 μM Incubation Duration: 24 hours Experimental Results: Induced accumulation of sub-G1 and G1 phase cells in RUNX1/ETO positive SKNO-1 cells, while reducing S phase and G2/M phase cells, but did not affect the cell cycle stage of RUNX1/ETO negative THP-1 cells. |
| References |
| Molecular Formula |
C21H25N3O3S
|
|---|---|
| Molecular Weight |
399.51
|
| CAS # |
923865-06-9
|
| Appearance |
Light yellow to brown solid
|
| SMILES |
CC1=CSC2=NC(CNC(C(C)C)C3=CC4=C(OCCCO4)C=C3)=CC(N12)=O
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO : ~25 mg/mL (~62.58 mM; with sonication)
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 2.5031 mL | 12.5153 mL | 25.0307 mL | |
| 5 mM | 0.5006 mL | 2.5031 mL | 5.0061 mL | |
| 10 mM | 0.2503 mL | 1.2515 mL | 2.5031 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
